Integrative genomic analyses of sporadic clear cell Renal Cell Carcinoma define disease subtypes and potential new therapeutic targets

Por Dondeti, Vijay R., Wubbenhorst, Bradley, Lal, Priti, Gordan, John D., D'Andrea, Kurt, Attiyeh, Edward F., Simon, M. Celeste, Nathanson, Katherine L.
Publicado em 2011

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

Por Jilaveanu, Lucia B., Zhao, Fengmin, Zito, Christopher R., Kirkwood, John M., Nathanson, Katherine L., D'Andrea, Kurt, Wilson, Melissa, Rimm, David L., Flaherty, Keith T., Lee, Sandra J., Kluger, Harriet M.
Publicado em 2013

Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

Por Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Publicado em 2014

The FBXO4 Tumor Suppressor Functions as a Barrier to Braf(V600E)-Dependent Metastatic Melanoma

Por Lee, Eric K., Lian, Zhaorui, D'Andrea, Kurt, Letrero, Richard, Sheng, WeiQi, Liu, Shujing, Diehl, J. Nathaniel, Pytel, Dariusz, Barbash, Olena, Schuchter, Lynn, Amaravaradi, Ravi, Xu, Xiaowei, Herlyn, Meenhard, Nathanson, Katherine L., Diehl, J. Alan
Publicado em 2013

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2 negative patients with early onset breast cancer

Por Maxwell, Kara N., Wubbenhorst, Bradley, D’Andrea, Kurt, Garman, Bradley, Long, Jessica M., Powers, Jacquelyn, Rathbun, Katherine, Stopfer, Jill E., Zhu, Jiajun, Bradbury, Angela R., Simon, Michael S., DeMichele, Angela, Domchek, Susan M., Nathanson, Katherine L.
Publicado no Genet Med (2014)

Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas

Por Fishbein, Lauren, Khare, Sanika, Wubbenhorst, Bradley, DeSloover, Daniel, D’Andrea, Kurt, Merrill, Shana, Cho, Nam Woo, Greenberg, Roger A., Else, Tobias, Montone, Kathleen, LiVolsi, Virginia, Fraker, Douglas, Daber, Robert, Cohen, Debbie L., Nathanson, Katherine L.
Publicado no Nat Commun (2015)

Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma

Por Wilson, Melissa A., Zhao, Fengmin, Khare, Sanika, Roszik, Jason, Woodman, Scott E., D'Andrea, Kurt, Wubbenhorst, Bradley, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Schuchter, Lynn M., Lee, Sandra J., Flaherty, Keith T., Nathanson, Katherine L.
Publicado no Clin Cancer Res (2015)

Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors

Por Koster, Roelof, Mitra, Nandita, D'Andrea, Kurt, Vardhanabhuti, Saran, Chung, Charles C., Wang, Zhaoming, Loren Erickson, R., Vaughn, David J., Litchfield, Kevin, Rahman, Nazneen, Greene, Mark H., McGlynn, Katherine A., Turnbull, Clare, Chanock, Stephen J., Nathanson, Katherine L., Kanetsky, Peter A.
Publicado em 2014

A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility

Por Kanetsky, Peter A., Mitra, Nandita, Vardhanabhuti, Saran, Vaughn, David J., Li, Mingyao, Ciosek, Stephanie L., Letrero, Richard, D'Andrea, Kurt, Vaddi, Madhavi, Doody, David R., Weaver, JoEllen, Chen, Chu, Starr, Jacqueline R., Håkonarson, Håkon, Rader, Daniel J., Godwin, Andrew K., Reilly, Muredach P., Schwartz, Stephen M., Nathanson, Katherine L.
Publicado em 2011

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436)

Por Nathanson, Katherine L., Martin, Anne-Marie, Wubbenhorst, Bradley, Greshock, Joel, Letrero, Richard, D’Andrea, Kurt, O’Day, Steven, Infante, Jeffrey R., Falchook, Gerald S., Arkenau, Hendrik-Tobias, Millward, Michael, Brown, Michael P., Pavlick, Anna, Davies, Michael A., Ma, Bo, Gagnon, Robert, Curtis, Martin, Lebowitz, Peter F., Kefford, Richard, Long, Georgina V.
Publicado em 2013

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K

Por Villanueva, Jessie, Vultur, Adina, Lee, John T., Somasundaram, Rajasekharan, Fukunaga-Kalabis, Mizuho, Cipolla, Angela K., Wubbenhorst, Bradley, Xu, Xiaowei, Gimotty, Phyllis A., Kee, Damien, Santiago-Walker, Ademi E., Letrero, Richard, D’Andrea, Kurt, Pushparajan, Anitha, Hayden, James E., Brown, Kimberly Dahlman, Laquerre, Sylvie, McArthur, Grant A., Sosman, Jeffrey A., Nathanson, Katherine L., Herlyn, Meenhard
Publicado em 2010

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Por Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N., Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Tsang, Garson, West, Brian L., Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam Y. J., Artis, Dean R., Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D'Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S., Lee, Richard J., Grippo, Joseph, Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., Chapman, Paul B., Flaherty, Keith T., Xu, Xiaowei, Nathanson, Katherine L., Nolop, Keith
Publicado em 2010